Compare Mitsubishi UFJ Financial Group Inc. Common Stock (MUFG) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mitsubishi UFJ Financial Group Inc. Common Stock vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Mitsubishi UFJ Financial Group Inc. Common Stock trades at $22.38 (market cap $249.48B), while Nuvation Bio Inc. Class A Common Stock trades at $5 (market cap $1.74B). The key difference: Mitsubishi UFJ Financial Group Inc. Common Stock is far larger — about 143.4× Nuvation Bio Inc. Class A Common Stock's market cap, and Mitsubishi UFJ Financial Group Inc. Common Stock pays a 2.4% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mitsubishi UFJ Financial Group Inc. Common Stock for 0 Days and Nuvation Bio Inc. Class A Common Stock for 1 Days on average.
| MUFG | NUVB | |
|---|---|---|
Market Cap | $249.48B | $1.74B |
Volume | 4,008,160 | 9,289,619 |
Sector | Financials | Health |
52-Week High | $24.13 | $9.54 |
52-Week Low | $14.62 | $3.41 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $28.96T | $1.33B |
Dividend Yield | 2.4% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mitsubishi UFJ Financial Group Inc. Common Stock
Mitsubishi UFJ Financial Group is a Japanese financial services company providing banking, lending, securities, and asset management services. Its businesses serve individuals, companies, and institutions worldwide.
Read more on MUFG →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
